Bioiberica to highlight new research on its native type II collagen at Vitafoods Europe 2024


The study shows that its Collavant n2 can alleviate joint discomfort in healthy subjects.

Photo © Kaulitzki

Photo © Kaulitzki

At this year’s Vitafoods Europe, Bioiberica (Barcelona, Spain) will be at booth F142, sharing the results from an anticipated new clinical trial of its native type II collagen, Collavant n2. According to the company, the results were presented for the first time at Osteoarthritis Research Society International (OARSI) World Congress on Osteoarthritis.

The study, conducted in collaboration with Poal Institute of Rheumatology in Barcelona, Spain, evaluated the efficacy and tolerability of Collavant n2 on the joint function of healthy volunteers who were experiencing joint discomfort from post-intensive exercise. Volunteers took 40 mg per day of the native collagen or placebo for six months and were assessed at intervals of 60, 90, 120 and 180 days using KOOS (Knee Injury and Osteoarthritis Outcome Score).Results showed that volunteers saw significant reductions in joint discomfort after 120 days, with improvements in quality of life observed after 90 days compared to baseline. Additionally, study volunteers that had basal activity-related discomfort (VAS < 4cm), saw statistically significant improvements compared to placebo at 180 days for both joint discomfort and quality of life.

“This marks the first exploration of Collavant n2’s effects in healthy individuals, and not just those with joint health conditions,” said Ingrid Möller MD, PhD, in a press release. Möller is a rheumatologist at Poal Institute of Rheumatology in Barcelona and lead investigator of the trial. “In my view, native type II collagen is a pro-health nutritional solution and this research confirms my belief that it could be beneficial for ‘everyday consumers’ leading active lifestyles or regularly engaged in sports; a demographic that continues to grow,” added Möller.

“This research could be a gamechanger in the field of nutrition innovation,” said Daniel Martínez-Puig, head of R&D Human and Animal Health at Bioiberica and another investigator on the study. “Not only were the initial findings promising, but the positive effects of Collavant n2 were observed after just three months. This suggests the ingredient could therefore contribute to overall satisfaction and compliance with products featuring it.”

Related Videos
Nils Hoem and Nutritional Outlook editor Sebastian Krawiec
woman working on laptop computer by window
Related Content
© 2024 MJH Life Sciences

All rights reserved.